http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8216835-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_337216930366a500d6a547db1a4a7566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9805ebffbf4ff1dce28719181b004630 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
| filingDate | 2009-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9a34ab111c993dcdf40e747f1e363f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0643370ac79ee97f354617ac5ba1f39f |
| publicationDate | 2012-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8216835-B2 |
| titleOfInvention | Modulating the CDC14B-CDH1-PLK1 axis and methods for sensitizing target cells to apoptosis |
| abstract | The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders. |
| priorityDate | 2008-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 144.